Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7963438 | 0.90 | ALDH1A1 (0.32) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL7946704 | 0.86 | CYP11B2 (0.39) | CYP11B2CYP11B1 | |
| SCHEMBL7963272 | 0.81 | GSK3B (0.32) | — | |
| SCHEMBL8328950 | 0.81 | DHODH (0.37) | — | |
| SCHEMBL7964663 | 0.80 | CYP11B2 (0.41) | CYP11B2PDE10ACYP11B1SQORKDM4E | |
| SCHEMBL7952322 | 0.80 | SQOR (0.34) | SQOR | |
| SCHEMBL7961829 | 0.80 | IDO1 (0.35) | ALDH1A1MAPTHPGD | |
| SCHEMBL7960341 | 0.78 | CYP11B2 (0.42) | CYP11B2CYP11B1 | |
| SCHEMBL7968043 | 0.75 | KDM4E (0.32) | KDM4EALDH1A1GAA | |
| SCHEMBL7946457 | 0.74 | ALDH1A1 (0.42) | CYP11B2KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | claimed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | claimed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | claimed |
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | disclosed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |